Compare Cipla with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs JUBILANT PHARMOVA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA JUBILANT PHARMOVA CIPLA/
JUBILANT PHARMOVA
 
P/E (TTM) x 34.3 14.2 241.4% View Chart
P/BV x 4.9 2.7 182.7% View Chart
Dividend Yield % 0.4 0.6 75.1%  

Financials

 CIPLA   JUBILANT PHARMOVA
EQUITY SHARE DATA
    CIPLA
Mar-20
JUBILANT PHARMOVA
Mar-19
CIPLA/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs586898 65.2%   
Low Rs357618 57.8%   
Sales per share (Unadj.) Rs207.0572.0 36.2%  
Earnings per share (Unadj.) Rs18.636.2 51.3%  
Cash flow per share (Unadj.) Rs33.259.5 55.7%  
Dividends per share (Unadj.) Rs4.004.50 88.9%  
Dividend yield (eoy) %0.80.6 143.0%  
Book value per share (Unadj.) Rs195.5301.9 64.7%  
Shares outstanding (eoy) m806.35159.28 506.2%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.31.3 171.8%   
Avg P/E ratio x25.320.9 121.1%  
P/CF ratio (eoy) x14.212.7 111.6%  
Price / Book Value ratio x2.42.5 96.0%  
Dividend payout %21.512.4 173.2%   
Avg Mkt Cap Rs m379,912120,694 314.8%   
No. of employees `00025.82.4 1,081.4%   
Total wages/salary Rs m30,27019,260 157.2%   
Avg. sales/employee Rs Th6,459.638,120.6 16.9%   
Avg. wages/employee Rs Th1,171.28,058.4 14.5%   
Avg. net profit/employee Rs Th580.22,414.3 24.0%   
INCOME DATA
Net Sales Rs m166,94991,108 183.2%  
Other income Rs m3,442357 963.1%   
Total revenues Rs m170,39191,466 186.3%   
Gross profit Rs m32,06017,390 184.4%  
Depreciation Rs m11,7473,709 316.7%   
Interest Rs m1,9742,198 89.8%   
Profit before tax Rs m21,78211,840 184.0%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m6,3123,268 193.1%   
Profit after tax Rs m14,9955,770 259.9%  
Gross profit margin %19.219.1 100.6%  
Effective tax rate %29.027.6 105.0%   
Net profit margin %9.06.3 141.8%  
BALANCE SHEET DATA
Current assets Rs m117,03845,848 255.3%   
Current liabilities Rs m43,93120,897 210.2%   
Net working cap to sales %43.827.4 159.9%  
Current ratio x2.72.2 121.4%  
Inventory Days Days9657 168.5%  
Debtors Days Days8551 167.0%  
Net fixed assets Rs m107,42465,498 164.0%   
Share capital Rs m1,613159 1,012.2%   
"Free" reserves Rs m156,01847,930 325.5%   
Net worth Rs m157,63048,089 327.8%   
Long term debt Rs m23,69342,429 55.8%   
Total assets Rs m236,626114,685 206.3%  
Interest coverage x12.06.4 188.5%   
Debt to equity ratio x0.20.9 17.0%  
Sales to assets ratio x0.70.8 88.8%   
Return on assets %7.26.9 103.2%  
Return on equity %9.512.0 79.3%  
Return on capital %12.812.4 103.4%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03612,422 451.1%   
Fx outflow Rs m6,76417,227 39.3%   
Net fx Rs m49,272-4,805 -1,025.4%   
CASH FLOW
From Operations Rs m30,68511,215 273.6%  
From Investments Rs m1,040-10,118 -10.3%  
From Financial Activity Rs m-29,4886,574 -448.5%  
Net Cashflow Rs m2,3407,612 30.7%  

Share Holding

Indian Promoters % 16.0 45.6 35.1%  
Foreign collaborators % 20.8 3.5 594.3%  
Indian inst/Mut Fund % 12.2 8.7 140.2%  
FIIs % 23.7 21.2 111.8%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 21.1 124.2%  
Shareholders   161,166 23,815 676.7%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   CADILA HEALTHCARE  TTK HEALTHCARE  NEULAND LABS  BIOCON   J.B.CHEMICALS  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Apr 20, 2021 (Close)

TRACK CIPLA

CIPLA - ASTRAZENECA PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS